Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.
Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.
Disease progression among patients with metastatic lung, pancreatic, colorectal, and breast cancer is associated with statistically significant and clinically relevant reductions in health-related quality of life, real-world study data show.
The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.
In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.
Patients whose colon cancers are detected by routine screening have fewer postoperative complications than individuals whose cancers are diagnosed outside of a national programme, study findings indicate.
Minimally invasive liver surgery is associated with less postoperative morbidity, fewer major complications, and shorter hospital stays than open surgery among patients with colorectal liver metastases, Italian researchers report.
We cover three studies of colorectal cancer surveillance, one evaluating the relationship between adenomas at colonoscopy and the long-term incidence of cancer, while the other two investigate whether higher-intensity post-surgery follow-up improves outcomes.
Oxaliplatin-based hyperthermic intraperitoneal chemotherapy after cytoreductive surgery does not improve the survival of colorectal cancer patients with peritoneal carcinomatosis, the PRODIGE 7 investigators report.
The cost of metastatic colorectal cancer treatment in the USA is significantly more expensive than in Canada but does not achieve a greater survival benefit among patients, highlight findings reported at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.
The presence of the BRAF V600E mutation in colorectal liver metastases is associated with a worse prognosis and increased risk for recurrence, according to findings from an international retrospective cohort study.